Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer

Suguru Shirotake, Akira Miyajima, Takeo Kosaka, Nobuyuki Tanaka, Takahiro Maeda, Eiji Kikuchi, Mototsugu Oya

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: To determine whether angiotensin II type 1 receptor (AT1R) expression and tumor angiogenesis in human bladder cancer (BCa) specimens acquired by transurethral resection (TUR). It has recently been reported that AT1R is expressed in several tumors and is involved in tumor angiogenesis. However, no study has investigated AT1R expression in association with angiogenesis in clinical specimens of bladder cancer. Methods: Surgical specimens were obtained from 108 patients who had undergone TUR for bladder cancer. All specimens were pathologically diagnosed as urothelial carcinoma. AT1R expression and microvessel density (MVD) were determined by immunostaining. The clinical and pathologic characteristics were retrospectively reviewed. Results: The MVD was greater in muscle-invasive BCa (MIBC; 29 cases, 34.4 ± 4.1/0.25 mm2) than in non-MIBC (NMIBC; 79 cases, 17.4 ± 1.1/0.25 mm2, P < .0001). AT1R expression was greater in the MIBC (P = .0004) and high-grade (P = .0063) specimens than in the NMIBC and low-grade specimens. In addition, the greater expression of AT1R was significantly associated with MVD (P < .05). In NMIBC, the factors significantly affecting recurrence-free survival on univariate analysis were AT1R (P = .02), MVD (P < .0001), tumor multiplicity (P = .0007), and bacille Calmette-Guérin intravesical instillation after TUR (P = .0026). Multivariate analysis revealed that tumor multiplicity and no BCG intravesical instillation after TUR were independent predictors of 5-year recurrence-free survival, and AT1R and MVD were independent predictors of 1-year recurrence-free survival (P < .01). Conclusions: AT1R expression and MVD were related to early intravesical recurrence in NMIBC. The results suggest that AT1R could become a new molecular target and a prognostic factor for NMIBC.

Original languageEnglish
JournalUrology
Volume77
Issue number4
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Angiotensin Type 1 Receptor
Microvessels
Urinary Bladder Neoplasms
Intravesical Administration
Recurrence
Neoplasms
Survival
Mycobacterium bovis
Multivariate Analysis
Carcinoma
Muscles

ASJC Scopus subject areas

  • Urology

Cite this

Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. / Shirotake, Suguru; Miyajima, Akira; Kosaka, Takeo; Tanaka, Nobuyuki; Maeda, Takahiro; Kikuchi, Eiji; Oya, Mototsugu.

In: Urology, Vol. 77, No. 4, 04.2011.

Research output: Contribution to journalArticle

Shirotake, Suguru ; Miyajima, Akira ; Kosaka, Takeo ; Tanaka, Nobuyuki ; Maeda, Takahiro ; Kikuchi, Eiji ; Oya, Mototsugu. / Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. In: Urology. 2011 ; Vol. 77, No. 4.
@article{e9bce629a7df4059af4f49823a8cc395,
title = "Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer",
abstract = "Objectives: To determine whether angiotensin II type 1 receptor (AT1R) expression and tumor angiogenesis in human bladder cancer (BCa) specimens acquired by transurethral resection (TUR). It has recently been reported that AT1R is expressed in several tumors and is involved in tumor angiogenesis. However, no study has investigated AT1R expression in association with angiogenesis in clinical specimens of bladder cancer. Methods: Surgical specimens were obtained from 108 patients who had undergone TUR for bladder cancer. All specimens were pathologically diagnosed as urothelial carcinoma. AT1R expression and microvessel density (MVD) were determined by immunostaining. The clinical and pathologic characteristics were retrospectively reviewed. Results: The MVD was greater in muscle-invasive BCa (MIBC; 29 cases, 34.4 ± 4.1/0.25 mm2) than in non-MIBC (NMIBC; 79 cases, 17.4 ± 1.1/0.25 mm2, P < .0001). AT1R expression was greater in the MIBC (P = .0004) and high-grade (P = .0063) specimens than in the NMIBC and low-grade specimens. In addition, the greater expression of AT1R was significantly associated with MVD (P < .05). In NMIBC, the factors significantly affecting recurrence-free survival on univariate analysis were AT1R (P = .02), MVD (P < .0001), tumor multiplicity (P = .0007), and bacille Calmette-Gu{\'e}rin intravesical instillation after TUR (P = .0026). Multivariate analysis revealed that tumor multiplicity and no BCG intravesical instillation after TUR were independent predictors of 5-year recurrence-free survival, and AT1R and MVD were independent predictors of 1-year recurrence-free survival (P < .01). Conclusions: AT1R expression and MVD were related to early intravesical recurrence in NMIBC. The results suggest that AT1R could become a new molecular target and a prognostic factor for NMIBC.",
author = "Suguru Shirotake and Akira Miyajima and Takeo Kosaka and Nobuyuki Tanaka and Takahiro Maeda and Eiji Kikuchi and Mototsugu Oya",
year = "2011",
month = "4",
doi = "10.1016/j.urology.2010.11.002",
language = "English",
volume = "77",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer

AU - Shirotake, Suguru

AU - Miyajima, Akira

AU - Kosaka, Takeo

AU - Tanaka, Nobuyuki

AU - Maeda, Takahiro

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2011/4

Y1 - 2011/4

N2 - Objectives: To determine whether angiotensin II type 1 receptor (AT1R) expression and tumor angiogenesis in human bladder cancer (BCa) specimens acquired by transurethral resection (TUR). It has recently been reported that AT1R is expressed in several tumors and is involved in tumor angiogenesis. However, no study has investigated AT1R expression in association with angiogenesis in clinical specimens of bladder cancer. Methods: Surgical specimens were obtained from 108 patients who had undergone TUR for bladder cancer. All specimens were pathologically diagnosed as urothelial carcinoma. AT1R expression and microvessel density (MVD) were determined by immunostaining. The clinical and pathologic characteristics were retrospectively reviewed. Results: The MVD was greater in muscle-invasive BCa (MIBC; 29 cases, 34.4 ± 4.1/0.25 mm2) than in non-MIBC (NMIBC; 79 cases, 17.4 ± 1.1/0.25 mm2, P < .0001). AT1R expression was greater in the MIBC (P = .0004) and high-grade (P = .0063) specimens than in the NMIBC and low-grade specimens. In addition, the greater expression of AT1R was significantly associated with MVD (P < .05). In NMIBC, the factors significantly affecting recurrence-free survival on univariate analysis were AT1R (P = .02), MVD (P < .0001), tumor multiplicity (P = .0007), and bacille Calmette-Guérin intravesical instillation after TUR (P = .0026). Multivariate analysis revealed that tumor multiplicity and no BCG intravesical instillation after TUR were independent predictors of 5-year recurrence-free survival, and AT1R and MVD were independent predictors of 1-year recurrence-free survival (P < .01). Conclusions: AT1R expression and MVD were related to early intravesical recurrence in NMIBC. The results suggest that AT1R could become a new molecular target and a prognostic factor for NMIBC.

AB - Objectives: To determine whether angiotensin II type 1 receptor (AT1R) expression and tumor angiogenesis in human bladder cancer (BCa) specimens acquired by transurethral resection (TUR). It has recently been reported that AT1R is expressed in several tumors and is involved in tumor angiogenesis. However, no study has investigated AT1R expression in association with angiogenesis in clinical specimens of bladder cancer. Methods: Surgical specimens were obtained from 108 patients who had undergone TUR for bladder cancer. All specimens were pathologically diagnosed as urothelial carcinoma. AT1R expression and microvessel density (MVD) were determined by immunostaining. The clinical and pathologic characteristics were retrospectively reviewed. Results: The MVD was greater in muscle-invasive BCa (MIBC; 29 cases, 34.4 ± 4.1/0.25 mm2) than in non-MIBC (NMIBC; 79 cases, 17.4 ± 1.1/0.25 mm2, P < .0001). AT1R expression was greater in the MIBC (P = .0004) and high-grade (P = .0063) specimens than in the NMIBC and low-grade specimens. In addition, the greater expression of AT1R was significantly associated with MVD (P < .05). In NMIBC, the factors significantly affecting recurrence-free survival on univariate analysis were AT1R (P = .02), MVD (P < .0001), tumor multiplicity (P = .0007), and bacille Calmette-Guérin intravesical instillation after TUR (P = .0026). Multivariate analysis revealed that tumor multiplicity and no BCG intravesical instillation after TUR were independent predictors of 5-year recurrence-free survival, and AT1R and MVD were independent predictors of 1-year recurrence-free survival (P < .01). Conclusions: AT1R expression and MVD were related to early intravesical recurrence in NMIBC. The results suggest that AT1R could become a new molecular target and a prognostic factor for NMIBC.

UR - http://www.scopus.com/inward/record.url?scp=79953875357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953875357&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2010.11.002

DO - 10.1016/j.urology.2010.11.002

M3 - Article

VL - 77

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -